SCHEMBL768345

SCHEMBL768345

CCN(CC)c1cncc(-c2ccc3c(c2Cl)CC(=O)N3C)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.40
ALDH1A1 P00352 1/20 0.40
MAPT P10636 1/20 0.40
HPGD P15428 1/20 0.40
MAPK1 P28482 1/20 0.40
KMT2A Q03164 1/20 0.40
HSD17B10 Q99714 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
ACVRL1 P37023 14/20 0.39
ACVR1 Q04771 14/20 0.39
BMPR1A P36894 12/20 0.39
BMPR1B O00238 10/20 0.39
LMNA P02545 1/20 0.37
GAA P10253 1/20 0.37
TSPO P30536 1/20 0.37
TGFBR1 P36897 6/20 0.36
GABRP O00591 1/20 0.35
GABRD O14764 1/20 0.35
CACNA1F O60840 1/20 0.35
ALB P02768 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL769387 0.85 LMNA (0.41) ACVRL1ACVR1BMPR1ABMPR1BLMNA
SCHEMBL769027 0.83 CYP11B2 (0.41) ACVRL1ACVR1BMPR1ABMPR1BLMNA
SCHEMBL769240 0.82 CYP11B1 (0.41) ACVRL1ACVR1BMPR1ABMPR1BLMNA
SCHEMBL769004 0.81 CYP11B2 (0.44) ACVRL1ACVR1BMPR1ABMPR1BLMNA
SCHEMBL749146 0.81 BMPR1A (0.40) ACVRL1ACVR1BMPR1ABMPR1BLMNA
SCHEMBL750894 0.81 BMPR1A (0.40) ACVRL1ACVR1BMPR1ABMPR1BLMNA
SCHEMBL748251 0.80 CYP11B1 (0.42) ACVRL1ACVR1BMPR1ABMPR1BTGFBR1
SCHEMBL769604 0.80 CYP11B1 (0.40) ACVRL1ACVR1BMPR1ABMPR1BLMNA
SCHEMBL15869740 0.78 CYP11B1 (0.39) ACVRL1ACVR1BMPR1ABMPR1BLMNA
SCHEMBL768678 0.78 CYP11B1 (0.50) MEN1MAPTKMT2AACVRL1ACVR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140275175-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2014-09-18 US disclosed
US-20140275175-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2014-09-18 US disclosed
US-8778972-B2 5-pyridin-3-yl-1, 3-dihydro-indol-2-on derivatives and their use as modulators of aldosterone synthase and/or CYP11B1 NOVARTIS AG (CH) 2014-07-15 US disclosed
US-8778972-B2 5-pyridin-3-yl-1, 3-dihydro-indol-2-on derivatives and their use as modulators of aldosterone synthase and/or CYP11B1 NOVARTIS AG (CH) 2014-07-15 US disclosed
US-8778972-B2 5-pyridin-3-yl-1, 3-dihydro-indol-2-on derivatives and their use as modulators of aldosterone synthase and/or CYP11B1 NOVARTIS AG (CH) 2014-07-15 US disclosed
US-20120071512-A1 5-PYRIDIN-3-YL-1, 3-DIHYDRO-INDOL-2-ON DERIVATIVES AND THEIR USE AS MODULATORS OF ALDOSTERONE SYNTHASE AND/OR CYP11B1 NOVARTIS AG (CH) 2012-03-22 US disclosed
US-20120071512-A1 5-PYRIDIN-3-YL-1, 3-DIHYDRO-INDOL-2-ON DERIVATIVES AND THEIR USE AS MODULATORS OF ALDOSTERONE SYNTHASE AND/OR CYP11B1 NOVARTIS AG (CH) 2012-03-22 US disclosed
US-20120071512-A1 5-PYRIDIN-3-YL-1, 3-DIHYDRO-INDOL-2-ON DERIVATIVES AND THEIR USE AS MODULATORS OF ALDOSTERONE SYNTHASE AND/OR CYP11B1 NOVARTIS AG (CH) 2012-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140275175-A1 ORGANIC COMPOUNDS CYP11B2, CYP11B1, SLCO1B1 MEN1 1537/4885ALDH1A1 65/4885MAPT 1619/4885
US-20120071512-A1 5-PYRIDIN-3-YL-1, 3-DIHYDRO-INDOL-2-ON DERIVATIVES AND THEIR USE AS MODULATORS OF ALDOSTERONE SYNTHASE AND/OR CYP11B1 CYP11B1, HSD11B1, CYP11B2 MEN1 1681/4885ALDH1A1 330/4885MAPT 2075/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.